Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market: Major Trends Reshaping the Future of the Industry

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

What Will the Alpha-1 Antitrypsin Deficiency Augmentation Therapy Industry Market Size Be by 2025?
The market size for alpha-1 antitrypsin deficiency augmentation therapy has seen significant expansion in the past few years. The market will surge from a value of $1.69 billion in 2024 to around $1.82 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 7.3%. Factors such as enhanced diagnostic procedures, awareness drives, clinical studies, and the aging demographic have contributed to this growth during the historic period.

What's the Long-Term Growth Forecast for the Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size Through 2029?
Anticipations suggest robust escalation in the market size of alpha-1 antitrypsin deficiency augmentation therapy. It is projected to reach a value of $2.47 billion by 2029, accelerating at a compound annual growth rate (CAGR) of 7.9%. The projected growth over this period can be attributed to factors such as advancements in telehealth, remote monitoring, precision medicine, and gene therapy. Key trends during this forecast period are expected to include comprehensive safety and effectiveness data, models of care that focus on the patient, programs for tele-rehabilitation, and customized dosage plans.

View the full report here:
https://www.thebusinessresearchcompany.com/report/alpha-1-antitrypsin-deficiency-augmentation-therapy-global-market-report

What Are the Key Growth Drivers Fueling the Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Expansion?
An uptick in respiratory diseases is fostering growth in the alpha-1 antitrypsin deficiency augmentation therapy market. Respiratory conditions, which can hamper lung and overall respiratory system function, can lead to breathing struggles and a loss of lung function. Individuals with alpha-1 antitrypsin deficiency can use this augmentation therapy to address their respiratory diseases. It works by supplementing the deficient protein and restoring protease-antiprotease activity balance within the lungs. This helps protect lung tissue from damage and reduce inflammation. The Centers for Disease Control and Prevention reported that the number of tuberculosis (TB) cases in the United States increased from 7,874 in 2021 to 8,300 in 2022. This rise in respiratory diseases is accelerating the therapy market's growth. The Growing Number of Clinical Trials Will Likely Accelerate the Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13006&type=smp

What Are the Key Trends Driving Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Growth?
In the acute respiratory distress syndrome (ARDS) market, key players are concentrating their efforts on creating new therapies such as drug development based on recombinant technology to maintain their market presence. The production of therapeutic pharmaceuticals employs recombinant DNA technology, involving the alteration of living organisms' DNA to produce specific proteins. For example, Inhibrx Inc., a biotech company from the US, announced in March 2022 that the U.S. Food and Drug Administration (FDA) awarded its product, INBRX-101, an orphan drug designation. This designation was granted for the treatment of alpha-1 antitrypsin deficiency (AATD). INBRX-101 is a recombinant human AAT-Fc fusion protein, with the potential of being administered once a month. Its aim is to safely reach and sustain the levels of AAT found in healthy individuals.

How Is the Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Segmented?
The alpha-1 antitrypsin deficiency augmentation therapy market covered in this report is segmented -

1) By Product Type: Glassia, Aralast NP, Prolastin C, Zemaira And Respreeza
2) By Route Of Administration: Oral, Injection, Inhalation
3) By End User: Hospitals, Specialty Clinics, Other End Users

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=13006&type=smp

Which Companies Are Leading the Charge in Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Innovation?
Major companies operating in the alpha-1 antitrypsin deficiency augmentation therapy market are Pfizer Inc., Sanofi S.A., AstraZeneca PLC, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Amgen Inc., Baxter International Inc., CSL Limited, Biogen Inc., Vertex Pharmaceuticals Incorporated, Grifols S.A., BioMarin Pharmaceutical Inc., LFB Group, Octapharma AG, Arrowhead Pharmaceuticals Inc., Kamada Ltd., Krystal Biotech Inc., Intellia Therapeutics Inc., Mereo BioPharma Group PLC, Protalix BioTherapeutics Inc., Centessa Pharmaceuticals Limited, Inhibrx Inc., Liminal BioSciences Inc., Applied Genetic Technologies Corporation, Abeona Therapeutics Inc.

Which Regions Are Leading the Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market in Revenue?
North America was the largest region in the alpha-1 antitrypsin deficiency augmentation therapy market in 2024. The regions covered in alpha-1 antitrypsin deficiency augmentation therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13006

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 7882 955267,
Asia: +91 88972 63534,
Americas: +1 310-496-7795 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.